CorMedix CRMD Employee and contracted employee expense — Total research and development
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by CorMedix in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: CorMedix’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about CorMedix's employee and contracted employee expense — total research and development.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CorMedix's employee and contracted employee expense — total research and development?
- CorMedix (CRMD) reported employee and contracted employee expense — total research and development of $2.34M in Q1 2026.
- What does employee and contracted employee expense — total research and development mean?
- This metric represents the total personnel-related costs, including salaries, benefits, and external contractor fees, specifically allocated to research and development activities. It reflects the company's investment in clinical trials, drug discovery, and regulatory compliance efforts. Monitoring this expense helps investors assess the company's commitment to pipeline innovation and the efficiency of its R&D operations.